Gilead Expands Deal and Triples Tango Targets to 15

By Michelle Liu

Pharma Deals Review: Vol 2020 Issue 8 (Table of Contents)

Published: 26 Aug-2020

DOI: 10.3833/pdr.v2020.i8.2558     ISSN: 1756-7874

Section: Research & Development



Continuing to invest in its immuno-oncology portfolio, Gilead Sciences has agreed to expand its collaboration with Tango Therapeutics to increase the number of targets from five to 15...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details